Court decision puts Guidant/Cook deal in doubt
This article was originally published in Clinica
Guidant's proposed acquisition of Cook is looking uncertain after a US district court in Illinois granted Boston Scientific's request for a permanent injunction against Guidant co-developing a drug-coated stent with Cook.
You may also be interested in...
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.